Last reviewed · How we verify

Hidradenitis suppurativa — Treatment Landscape & Competitive Intelligence

Hidradenitis suppurativa (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hidradenitis suppurativa, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Abrilada Adalimumab-Afzb AbbVie TNF blocker Tumor necrosis factor-alpha (TNF-alpha) 2002-01-01
Humira ADALIMUMAB AbbVie TNF blocker Tumor Necrosis Factor-alpha (TNF-alpha) 2002-01-01
CYLTEZO ADALIMUMAB-ADBM BOEHRINGER INGELHEIM Tumor necrosis factor
Humira Humira Sohag University Tumor necrosis factor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. AbbVie · 2 drugs in Hidradenitis suppurativa
  2. BOEHRINGER INGELHEIM · 1 drug in Hidradenitis suppurativa
  3. Sohag University · 1 drug in Hidradenitis suppurativa

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hidradenitis suppurativa:

Cite this brief

Drug Landscape (2026). Hidradenitis suppurativa — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hidradenitis-suppurativa. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing